Clinical Trial
NCT05063162 Recruiting, Active
cosMOG
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)
Disease
Disease type
MOGAD
Patient type
Adult
Children
Inclusion / Exclusion
Funding
private
Members involved
Others investigators
Pr Paul Friedemann
Representative
Germany
Neuro-Ophthalmology Rare Diseases (WG2), Registries & Epidemiology (TWG7), Research (TWG8)
Pr Bart LEROY
Representative
Belgium
Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
ERN EYE member investigating site
HCP : Principal investigators
Charité – Universitätsmedizin Berlin, Germany
Adress
Charitépl. 1
10117 Berlin
Germany
Ghent University Hospital, Ghent, Belgium
Adress
Corneel Heymanslaan 10
9000 Ghent
Belgium